Recurrence Score News Today

MADISON, Wis.--(BUSINESS WIRE)--Feb 28, 2024--

Exact Sciences Corporation (NASDAQ: EXAS) shares are trading higher Wednesday, and the stock has gained over 8% in the past month. Here's a look at the latest Exact Sciences news: What To Know:

For postmenopausal women aged 50 to 69 years with stage 1 hormone receptor-positive breast cancer, the risk for recurrence is very low for those who do not undergo radiotherapy after BCS.

Avoiding unnecessary chemotherapy

Unveiling the Strengths and Challenges: A Deep Dive into Exact Sciences Corp (EXAS) SWOT Analysis

MADISON, Wis., Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, tod...

MADISON, Wis., Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the companys...

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data...

Resolution Bioscience’s blood-based diagnostic tests complement Exact Sciences’ Precision Oncology portfolio, providing a more complete cancer treatment solution for patients, healthcare...

MADISON - Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June...